In addition to that, further investigation is necessary to evaluate the therapeutic potential of Gal-3 for ICC patients or those comprised with COVID-19 despite well-documented roles of Gal-3 in inflammation and cancer. This evidence concerns the gene LGALS3 and COVID-19.